辉瑞(PFE)盘前跌超1% 终止两项治疗呼吸道合胞病毒感染的临床研究

金吾财讯
10 Oct 2024

金吾财讯 | 辉瑞(PFE)盘前跌超1%,截至发稿,报29.8美元。消息面上,辉瑞已终止两项Sisunatovir治疗呼吸道合胞病毒(RSV)感染的临床研究。Sisunatovir是一种口服RSV融合蛋白抑制剂,旨在阻止RSV病毒与宿主细胞的融合。辉瑞发言人表示:“Sisunatovir的临床开发面临持续的挑战,包括与抗酸药的药物相互作用。虽然辉瑞一直在努力解决这些挑战,但最终决定终止Sisunatovir的开发,以集中精力发现和推进其他在研疗法的开发,这些疗法最有可能预防和治疗RSV疾病和其他呼吸道病毒感染。”

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10